Innovative Leukemia and Lymphoma Therapy Contributor(s): Kaspers, Gertjian J. L. (Editor), Coiffier, Bertrand (Editor), Heinrich, Michael C. (Editor) |
|
![]() |
ISBN: 0849350832 ISBN-13: 9780849350832 Publisher: CRC Press OUR PRICE: $171.00 Product Type: Hardcover - Other Formats Published: May 2008 Annotation: Written by international experts in the field," "this new guideexamines cutting-edge clinical studies that investigate innovative therapies and related topics for leukemia and lymphoma including: - tyrosine kinase inhibitors, histon deacetylase inhibitors, and farnesyl transferase inhibitors - radioimmunotherapy, gene-directed therapy, and immunotherapy by vaccination - monoclonal antibodies - anti-angiogenesis approaches - the concerns of conventional but novel anticancer agents - modulation of classical multidrug resistance - modulators of single agent drug resistance. "Innovative Leukemia and Lymphoma Therapy" is the only comprehensive and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma in practice today |
Additional Information |
BISAC Categories: - Medical | Oncology - General - Medical | Hematology |
Dewey: 616.994 |
LCCN: 2008006553 |
Series: Basic and Clinical Oncology |
Physical Information: 1.43" H x 6.39" W x 8.97" (2.06 lbs) 616 pages |
Descriptions, Reviews, Etc. |
Publisher Description: Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as:
Within each chapter, this well-illustrated, comprehensive source provides a summary of the rationale for treatment, the pathways that are involved, and the translational research to students, scientists, and clinicians. In addition, this book focuses on the concerns of conventional but novel anticancer agents, modulation of classical multidrug resistance, and modulators of single agent drug resistance. |